In the red-hot world of antibodies, cancer specialist Genmab is one to watch.
Notably, Q3 2015 was a busy one for Genmab, with submissions for two antibodies fast-tracked in the US and one in Europe (the second pending), and a new DuoBody platform license deal with Novo Nordisk.
“The antibody field is without borders,” says Genmab SVP and Scientific Director Dr. Paul Parren.
“These are very versatile molecules that are widely applicable in many disease areas and able to engage many different mechanisms.”
We caught up with Parren to discuss development trends in the space.
“The antibody field is really moving away from naked antibodies or unmodified antibody drugs,” Parren noted.
“We see a lot of interest in new formats, mostly because we really think that we need to make more potent antibodies,” he added.
In this podcast interview for Inside Antibody Engineering, Dr. Parren discusses the future of antibody engineering and key trends including:
• Combination treatments
• Personalized medicine and more…
Listen to the podcast or download a transcript here!
Editor’s note: Dr. Paul Parren will be chairing the “Antibody Effector Functions” track at the Antibody Engineering and Therapeutics Conference taking place December 7-10 in San Diego.
Click here for an agenda.
Or for more information visit: www.ibclifesciences.com/antibodyeng
(Ps. SAVE $100 when you register with code D15172BLOG!)
ABOUT THE AUTHOR/INTERVIEWER
Marc Dresner is sr. editor and special communication project lead with IBC Life Sciences. He is the former executive editor of Pharma Market Research Report, a publication for market research professionals specializing in pharmaceuticals and life sciences. He may be reached at email@example.com. Follow him @mdrezz.
Share this article with your social network, just click below to share now!